TickerTalks
Browse all tickers →
TickerTalks›$RXRX
RXRXRX

Recursion Pharmaceuticals, Inc.

$RXRX·$1.7B·Biotechnology·Healthcare
$3.40+1.8%YTD-20.6%1Y-27.0%
Mentions · last 7 days
2026-08-21: 41 posts2026-08-22: 19 posts220+9%
Price updated 2h ago·X counts updated 9d ago
RXRXRX
$RXRXRecursion Pharmaceuticals, Inc.
$3.40+1.80%220 posts+9%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $RXRX, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventWinding up for a moveAI verdict · as of 2026-08-29

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Recursion at $3.34 approaching the 50-week MA with a Roche/MRNA-driven AI-biotech rotation — clinical-data catalysts are the whole trade.

Recursion Pharmaceuticals is an AI-driven drug-discovery platform — using computational biology and phenomics to accelerate lead identification, with partnerships with Roche/Genentech and Bayer plus a wholly-owned pipeline in oncology and rare diseases. The setup is a catalyst-play into fresh AI-biotech attention.

  • The AI-biotech sector rotation is a fresh tailwind: the MRNA-driven cancer-vaccine wave has broadened into AI-drug-discovery names, and RXRX is +10% weekly approaching its 50-week moving average with chart-heads calling a tight descending-wedge breakout — the sector rerating gives Recursion a real bid it hasn't had for a year.
  • The Roche progress is the fundamental anchor: Q2 highlights included AI platform updates plus continued Roche/Genentech collaboration progress, but revenue was still $6.5M (down 56% YoY as legacy collaboration revenue rolled off), gross margin -93%, and operating margin -1,986% — the multiple only works on the pipeline.
  • The institutional and insider signals are mixed: CalSTRS increased its RXRX stake mid-August, and Bank of America Corp DE holds it — but the insider action is only F-InKind (tax-withholding) plus a small $97K director sale on August 4; no open-market buys at the depressed levels the setup would want.

The setup is a catalyst-play coil where the trigger is clinical-pipeline progress plus the AI-biotech rotation continuing — the November 4 Q3 print and any Roche milestone or wholly-owned Phase 1/2 readout is the referee. A named Roche milestone payment or a positive REC-4881 (or similar) data readout breaks the coil up toward $5; another quarter of $6M revenue with no pipeline update keeps the stock coiled below $4.

Agrees with X sentimentThe bullish X read on the MRNA-driven biotech AI rotation, RXRX +10% weekly approaching the 50WMA, and the tight descending-wedge breakout in progress with 373-379% wedge-top targets is factually consistent with the tape. The 373-379% target is aspirational but the AI-biotech rotation is real. CalSTRS increasing its RXRX stake and Recursion's Roche progress reinforce the setup.

What to watch: The November 4 Q3 earnings and any Roche milestone payment or wholly-owned pipeline data readout (REC-4881, REC-994, etc.). A named Roche milestone or positive Phase 1/2 data breaks the coil up toward $5; another quarter of $6M revenue with no pipeline update keeps the stock coiled below $4.

On the calendar: 2026-11-04 — Q3 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment8 posts analyzed · as of 2026-08-30

AI-healthcare posters are constructive on Recursion, framing it as a top-five biotech alongside TEM, SDGR and ABSI and highlighting a Genentech neuroscience target advancing into early discovery and REC-4881 in Phase 2. Chartists describe a tight descending wedge with 373% room to the upper bound and cite heavy open interest at the $3.50 and $4 strikes as a magnet. The one dip post is treated as a buying opportunity, not a warning.

Read the AI verdict + X sentiment for $RXRX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Uses AI and high-throughput biology to build drug discovery pipelines, combining biological maps with computational design.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $RXRX.

Biotechnology · Healthcare

GLP-1 oral formulation competition — emerging clinical data from pipeline challengers — is the central bifurcation: platform holders (LLY, NVO) defend on efficacy breadth while precision oncology names decouple entirely. FDA catalyst cadence over the next 60 days sets the near-term tone.

What this means for $RXRX

Partial — fee-based midstream revenue has limited direct commodity price exposure but volume ties to upstream production activity.

Top industry ETF

$IBBiShares Biotechnology ETF
+12.1%YTD
+48.9%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-3.1How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-47.1%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-8.8%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-22.0%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
22.4Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-54.3%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
-34.4%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.1Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 5, 2026$-0.25$-0.24-4.2%
Q1 2026May 6, 2026$-0.22$-0.30+26.7%
Q4 2025Feb 25, 2026$-0.21$-0.28+25.0%
Q3 2025Nov 5, 2025$-0.36$-0.38+5.3%
Next earningsWed, Nov 4·consensus EPS $-0.23

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$6.5M-56.1%-93.0%-1986%$-0.22$-81.4M
Q4 FY25$35.5M+687.8%24.4%-305%$-0.21$-47.3M
Q3 FY25$5.2M-80.2%-472%-3328%$-0.36$-117.6M
Q2 FY25$19.1M+32.6%-5.5%-923%$-0.41$-79.6M

Forward consensus

4-year forecast · up to 6 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$59.1M$22.3M – $78.6M-$0.93-$1.15 – -$0.786
FY27$83.8M$62.1M – $105.3M-$0.93-$1.18 – -$0.806
FY28$153.7M$153.7M – $153.7M-$0.76-$1.13 – -$0.283
FY29$247.5M$126.8M – $339.8M-$0.94-$1.40 – -$0.342

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.6×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.13%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+1.0%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-9.0%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatHigh float · 408.7M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.6% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.055-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellAug 4Blake BorgesonDirector30.0K sh$98KSellJul 7Blake BorgesonDirector40.0K sh$159KSellJun 18Namandje BumpusDirector4.0K sh$13KSellJun 5Christopher GibsonDirector40.0K sh$145KSellJun 5Najat KhanCEO23.6K sh$84KSellJun 3Namandje BumpusDirector4.4K sh$16KSellJun 2Blake BorgesonDirector30.0K sh$110KSellMay 22Christopher GibsonDirector40.0K sh$123KSellMay 7Christopher GibsonDirector40.0K sh$135KSellMay 5Blake BorgesonDirector30.0K sh$106K
1–10 of 16
+ 30 other (11 awards · 10 inkinds · 7 conversions · 2 gifts) in window

See when $RXRX insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KPress release / Reg FDAug 58-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
AI summary

RXRX filed an 8-K (Item 2.02) reporting its financial results for the second quarter June 30, 2026. A copy of the press release is furnished as Exhibi, filed 2026-08-05. The actual financial figures are in the attached press release (Exhibit 99.1), not reproduced in the body excerpt. This is a material disclosure; investors should review the press release for beat/miss details and guidance.

8-KShareholder voteJun 188-K — Item 5.07: Shareholder vote
AI summary

Delaware 001-40323 46-4099738 disclosed voting results from its annual or special meeting. hange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 5.07. Submission of Matters to a Vote of Security Holders. Recursion...

8-KPress release / Reg FDMay 68-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
AI summary

RXRX reported first quarter March 31, 2026. A copy of the press rel financial results (8-K Item 2.02). Investors should review the full earnings press release and any management guidance for forward outlook.

8-KOfficer or director changeApr 308-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
AI summary

RXRX disclosed a personnel change (8-K Item 5.02, dated 2026-04-30). An executive departure and a new appointment are both reported. Personnel changes are generally administrative; materiality depends on seniority and circumstances.

8-KOfficer or director changeMar 258-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
AI summary

RXRX disclosed a personnel change (8-K Item 5.02, dated 2026-03-25). An executive departure and a new appointment are both reported. Personnel changes are generally administrative; materiality depends on seniority and circumstances.

+ 12 other (7 13Gs · 2 10-Qs · 2 proxys · 1 ARS) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharmazacks.com·15d agoRecursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline Updatesdefenseworld.net·15d agoRecursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline Updatesmarketbeat.com·15d agoRecursion Pharmaceuticals, Inc. $RXRX Stake Increased by California State Teachers Retirement Systemdefenseworld.net·19d agoRecursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America SMID Cap Virtual Conference Transcriptseekingalpha.com·20d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRNA$ALT$AURA$IOVA$NWBO$SLS$AMLX$ABCL
Voices on X · top 5 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport